Advertisement

Topical Application of siRNA Targeting Cutaneous Dendritic Cells in Allergic Skin Disease

  • Miyuki Azuma
  • Patcharee Ritprajak
  • Masaaki Hashiguchi
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 623)

Abstract

RNA interference is a promising method for silencing specific genes and has great potential for therapeutic applications. However, the major hurdle for therapeutic application is the limited stability of double-strand RNA (dsRNA) and the absence of a reliable delivery method to target cells. Skin appears to be a favorable target for small interfering RNA (siRNA) therapy. Dendritic cells (DCs) exist in the skin and mucosae on the front lines of defense; these cells capture antigens and play a crucial role in inducing immunity and tolerance.

In our recent work, we have shown a successful treatment using CD86 siRNA targeting cutaneous DCs. A costimulatory molecule, CD86, is induced on DCs in situ after antigen uptake, and CD86-expressing DCs migrate to the regional lymph nodes to present antigens to T cells. Topical application of cream-emulsified CD86 siRNA ameliorated the clinical manifestations in murine contact hypersensitivity (CH) and atopic dermatitis (AD)-like disease. Our method may be advantageous for the treatment of allergic skin diseases.

Key words

Dendritic cells siRNA Topical application CD86 Costimulatory molecules Skin allergic disease 

Notes

Acknowledgments

This work was supported by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

  1. 1.
    Sharpe, A.H. and Freeman, G.J. (2002) The B7-CD28 superfamily. Nat. Rev. Immunol. 2, 116–126.CrossRefPubMedGoogle Scholar
  2. 2.
    Vincenti, F. (2008) Costimulation blockade in autoimmunity and transplantation. J. Allergy Clin. Immunol. 21, 299–306.CrossRefGoogle Scholar
  3. 3.
    Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y. J. et al. (2000) Immunobiology of dendritic cells. Annu. Rev. Immunol. 18, 767–811.CrossRefPubMedGoogle Scholar
  4. 4.
    Steinman, R.M. and Banchereau, J. (2007) Taking dendritic cells into medicine. Nature 449, 419–426.CrossRefPubMedGoogle Scholar
  5. 5.
    Jen, K.Y., Jain, V.V., Makani, S. and Finn, P.W. (2006) Immunomodulation of allergic responses by targeting costimulatory molecules. Curr. Opin. Allergy Clin. Immunol. 6, 489–494.CrossRefPubMedGoogle Scholar
  6. 6.
    Ohki, O., Yokozeki, H., Katayama, I., Umeda, T., Azuma, M., Okumura, K. et al. (1997) Functional CD86 (B7-2/B70) is predominantly expressed on Langerhans cells in atopic dermatitis. Br. J. Dermatol. 136, 838–845.CrossRefPubMedGoogle Scholar
  7. 7.
    Yokozeki, H., Katayama, I., Ohki, O., Arimura, M., Takayama, K., Matsunaga, T. et al. (1997) Interferon-gamma differentially regulates CD80 (B7-1) and CD86 (B7-2/B70) expression on human Langerhans cells. Br J Dermatol. 136, 831–837.CrossRefPubMedGoogle Scholar
  8. 8.
    Nuriya, S., Yagita, H., Okumura, K. and Azuma, M. (1996) The differential role of CD86 and CD80 co-stimulatory molecules in the induction and the effector phases of contact hypersensitivity. Int. Immunol. 8, 917–926.CrossRefPubMedGoogle Scholar
  9. 9.
    Katayama, I., Matsunaga, T., Yokozeki, H. and Nishioka, K. (1997) Blockade of costimulatory molecules B7-1 (CD80) and B7-2 (CD86) down-regulates induction of contact sensitivity by haptenated epidermal cells. Br. J. Dermatol. 136, 846–852.CrossRefPubMedGoogle Scholar
  10. 10.
    Santa, K., Watanabe, K., Nakada, T., Kato, H., Habu, S. and Kubota, S. (2003) Enhanced expression of B7.2 (CD86) by percutaneous sensitization with house dust mite antigen. Immunol. Lett. 85, 5–12.CrossRefPubMedGoogle Scholar
  11. 11.
    Ritprajak, P., Hashiguchi, M. and Azuma, M. (2008) Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells. Mol. Ther. 16, 1323–1330.CrossRefPubMedGoogle Scholar
  12. 12.
    Suto, H., Matsuda, H., Mitsuishi, K., Hira, K., Uchida, T., Unno, T. et al. (1999) NC/Nga mice: a mouse model for atopic dermatitis. Int. Arch. Allergy Immunol. 120 Suppl 1, 70–75.CrossRefPubMedGoogle Scholar
  13. 13.
    Matsuda, H., Watanabe, N., Geba, G.P., Sperl, J., Tsudzuki, M., Hiroi, J. et al. (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int. Immunol. 9, 461–466.CrossRefPubMedGoogle Scholar
  14. 14.
    Inoue, R., Nishio, A., Fukushima, Y. and Ushida, K. (2007) Oral treatment with probiotic Lactobacillus johnsonii NCC533 (La1) for a specific part of the weaning period prevents the development of atopic dermatitis induced after maturation in model mice, NC/Nga. Br. J. Dermatol. 156, 499–509.CrossRefGoogle Scholar
  15. 15.
    Takeda, K., Kaisho, T. and Akira, S. (2003) Toll-like receptors. Annu. Rev. Immunol. 21, 335–376.CrossRefPubMedGoogle Scholar
  16. 16.
    Cullen, B.R. (2006) Enhancing and confirming the specificity of RNAi experiments. Nat. Methods. 3, 677–681.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Miyuki Azuma
    • 1
  • Patcharee Ritprajak
    • 2
  • Masaaki Hashiguchi
    • 1
  1. 1.Department of Molecular ImmunologyGraduate School, Tokyo Medical and Dental UniversityTokyoJapan
  2. 2.Department of Microbiology and Immunology, Faculty of DentistryChulalongkorn UniversityBangkokThailand

Personalised recommendations